Assessment of Pregabalin-Induced Cardiotoxicity in Rats: Mechanistic Role of Angiotensin 1–7

• Published in: Cardiovascular toxicology Vol. 20; no. 3; pp. 301 - 311
• Main Authors: Awwad, Zeinab M., El-Ganainy, Samar O., ElMallah, Ahmed I., Khedr, Shaimaa M., Khattab, Mahmoud M., El-Khatib, Aiman S.
• Format: Journal Article
• Language: English
• Published: New York Springer US 01.06.2020; Springer; Springer Nature B.V
• Subjects: ACE2; Angiotensin; Angiotensin converting enzyme; Angiotensin II; Angiotensin-converting enzyme 2; Axes (reference lines); Biomedical and Life Sciences; Biomedicine; Brain natriuretic peptide; Cardiology; Cardiomyocytes; Cardiotoxicity; Chemical compounds; Congestive heart failure; Edema; Enzymes; Epilepsy; Ethylenediaminetetraacetic acid; Fibromyalgia; Health aspects; Natriuretic peptides; Neuralgia; Pain; Peptidyl-dipeptidase A; Pharmacology; Pharmacology/Toxicology; Pregabalin; Receptors; Renin; Diminazene aceturate; Angiotensin 1–7; Pregabalin; Cardiotoxicity
• ISSN: 1530-7905; 1559-0259
• DOI: 10.1007/s12012-019-09553-6

Pregabalin (PRG) possesses great therapeutic benefits in the treatment of epilepsy, neuropathic pain, and fibromyalgia. However, clinical data have reported incidence or exacerbation of heart failure following PRG administration. Experimental data exploring cardiac alterations and its underlying mechanisms are quite scarce. The aim of the present work was to investigate the effect of PRG on morphometric, echocardiographic, neurohumoral, and histopathological parameters in rats. It was hypothesized that alterations in cardiac renin angiotensin system (RAS) might be involved in PRG-induced cardiotoxicity. To further emphasize the role of RAS in the mechanism of PRG-induced cardiotoxicity, the protective potential of diminazene aceturate (DIZE), an ACE2 activator, was investigated. Results showed 44% decrease in ejection fraction and sevenfold increase in plasma N-terminal pro-brain natriuretic peptide. Histopathological examination also showed prominent vacuolar changes and edema in cardiomyocytes. In addition, PRG significantly increased angiotensin II (Ang II), angiotensin converting enzyme (ACE) and angiotensin II type 1 receptor (AT1R) levels, while decreased angiotensin 1–7 (Ang 1–7), angiotensin converting enzyme 2 (ACE2), and Mas receptor (MasR) cardiac levels. DIZE co-administration showed prominent protection against PRG-induced echocardiographic, neurohumoral, and histopathological alterations in rats. In addition, downregulation of ACE/Ang II/AT1R and upregulation of ACE2/Ang 1–7/MasR axes were noted in DIZE co-treated rats. These findings showed, for the first time, the detailed cardiac deleterious effects of PRG in rats. The underlying pathophysiological mechanism is probably mediated via altered balance between the RAS axes in favor to the ACE/Ang II/AT1R pathway. Accordingly, ACE2 activators might represent promising therapeutic agents for PRG-induced cardiotoxicity. Graphic Abstract